1-4 of 4
Nicholas Weber
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Prospective MRI and Neurocognitive Assessment of “Chemobrain” in Acute Myeloid Leukaemia: The Mineral Study

Ashleigh Scott, Ada Lo, Kate Thompson, Ying Xia, Harriet Bodimeade, Amir Fazlollahi, Cameron Curley, Steven W. Lane, Kirk Lachlan Morris, Caroline Jane McNamara, Elango S. Pillai, Nicholas Weber, Olivier Salvado, Katie L McMahon, Glen A Kennedy
Journal: Blood
Blood (2023) 142 (Supplement 1): 5850.
https://doi.org/10.1182/blood-2023-190301
Published: 2023
Journal Articles

A Phase I/II Single Arm Study of Belantamab Mafodotin, Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Planned Interim Analysis of Safety and Efficacy. Amarc 19-02 Belacard Study

Masa Lasica, Andrew Spencer, Noemi Horvath, Wojt Janowski, Douglas Coghlan, Craig Wallington-Gates, Philip Campbell, Hock Choong Lai, Georgia McCaughan, Nicholas Weber, Anish Puliyayil, Philip Wong, Deng Yachao, Khoa Le, John Reynolds, Hang Quach
Journal: Blood
Blood (2023) 142 (Supplement 1): 2012.
https://doi.org/10.1182/blood-2023-189005
Published: 2023
Journal Articles

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Peter Mollee, John Reynolds, Wojciech Janowski, Hang Quach, Philip Campbell, Simon D. Gibbs, Sophie Lee, James D'Rozario, Kerry Taylor, Tara Cochrane, Craig Thomas Wallington-Beddoe, Fiona Kwok, Nicholas Weber, Ian H Kerridge, Helen Weston, P. Joy Ho, Noemi Horvath, Flora Yuen, Andrew Spencer
Journal: Blood
Blood (2021) 138 (Supplement 1): 2728.
https://doi.org/10.1182/blood-2021-152500
Published: 2021
Journal Articles

A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Peter Mollee, FRACP,MBBS,MSc,FRCPA, John Reynolds, PhD, Wojt Janowski, FRCPA,FRACP, Hang Quach, MDFRACP,FRCPA,MBBS, Philip Campbell, MBBS, Simon D. Gibbs, FRACP, FRCPA, MBBS, Sophie Lee, FRACP, FRCPA, PhD, James D'Rozario, MBBS, FRACP, FRCPA, Kerry Taylor, FRACP,FRCPA,MBBS, Tara Cochrane, MBBS,FRCPA,FRACP, Craig Thomas Wallington-Beddoe, BSc,MBBS,PhDFRACP,FRCPA, Fiona Kwok, FRACP,FRCPA,MBBS, Nicholas Weber, MBBS, Ian H. Kerridge, FRACP FRCPA MPhil BA, Helen Weston, MBBS, FRACP, FRCPA, Phoebe Joy Ho, MBBS,DPhil,FRACP,FRCPA, Noemi Horvath, MB ChB FRACP FRCPA, Flora Yuen, BBiomedSc, Andrew Spencer
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–5.
https://doi.org/10.1182/blood-2020-138394
Published: 2020